Vanessa Molin
Nurse Practitioner · Philadelphia, PANPI 1760951131
Payments from drug & device makers
Across 338 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$926
- Boehringer Ingelheim$569
- Novo Nordisk$383
- AstraZeneca$338
- Bayer$307
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,44898%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $1,444 |
| GSK | 47 | $926 |
| Boehringer Ingelheim | 28 | $569 |
| Novo Nordisk | 20 | $383 |
| AstraZeneca | 20 | $338 |
| Bayer | 17 | $307 |
| Astellas Pharma US Inc | 10 | $306 |
| Corcept Therapeutics | 11 | $296 |
| Lilly USA, LLC | 13 | $259 |
| Johnson & Johnson | 11 | $211 |
| Exact Sciences | 10 | $209 |
| Teva Pharmaceuticals USA, Inc. | 8 | $142 |
| Sanofi-aventis U.S. LLC | 4 | $95 |
| Lundbeck LLC | 4 | $95 |
| Viiv Healthcare Company | 5 | $91 |
| Sumitomo Pharma America, Inc. | 4 | $90 |
| Pfizer | 5 | $87 |
| Merck | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $82 |
| Gilead | 4 | $80 |
| Novartis | 4 | $77 |
| Braeburn Inc. | 2 | $49 |
| Indivior Inc. | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $23 |
| Amgen | 1 | $20 |
| BD | 1 | $20 |
| Medtronic | 1 | $19 |
| Neurelis, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$6,604 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 170 | $143,185 |
| OzempicSemaglutide | 77 | $91,036 |
| TrulicityDulaglutide | 70 | $67,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $62,049 |
| FarxigaDapagliflozin Propanediol | 35 | $27,518 |
| EntrestoSacubitril/Valsartan | 27 | $26,945 |
| JanuviaSitagliptin Phosphate | 19 | $21,340 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $19,973 |
| XareltoRivaroxaban | 23 | $17,514 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 522 | $16,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,389 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 84 | $13,950 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $10,507 |
| EliquisApixaban | 17 | $9,755 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $569 | $143,185170 claims |
| Novo NordiskOzempic | $383 | $91,03677 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $926 | $85,186143 claims |
| Lilly USA, LLCTrulicity | $259 | $67,77470 claims |
| MerckJanuvia, Janumet | $86 | $41,31341 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $338 | $40,40368 claims |
| NovartisEntresto | $77 | $26,94527 claims |
| Johnson & JohnsonXarelto | $211 | $17,51423 claims |
| PfizerEliquis | $87 | $9,75517 claims |
| AbbVieLinzess | $1,444 | $8,31816 claims |
| Astellas Pharma US IncMyrbetriq | $306 | $6,37114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Philadelphia
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Carolyn GrandePhiladelphia$71K
- Faith MutalePhiladelphia$62K
- Frances RogersPhiladelphia$46K
- Meghan GarabedianPhiladelphia$30K
- Victoria SherryPhiladelphia$10K
- Tracey WileyChambersburg$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.